Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03005145 · ClinicalTrials.gov registry record · NA

Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness

A NA study of Sepsis and Bacteremia, sponsored by Sunnybrook Health Sciences Centre.

Completed
Registry status
NA
Development phase
3,622
Enrollment target
20
Study locations

NCT03005145 is a NA study of Sepsis and Bacteremia that has completed, run by Sunnybrook Health Sciences Centre. The registered enrollment target is 3,622 participants, below the 6,524-participant average among 90 other Sepsis trials with a reported enrollment target (44% lower). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03005145, a NA study of Sepsis and Bacteremia, has completed, sponsored by Sunnybrook Health Sciences Centre.

COMPLETED
Registry status
NA
Development phase
3,622 participants
Enrollment target
20
Study locations

Study Summary

The World Health Organization, U.S. Centers for Disease Control and Prevention, Association of Medical Microbiology and Infectious Diseases (AMMI) Canada, and Health Canada have all declared antimicrobial resistance a global threat to health, based on rapidly increasing resistance rates and declining new drug development. Up to 30-50% of antibiotic use is inappropriate, and excessive durations of treatment are the greatest contributor to inappropriate use. Shorter duration treatment (≤7 days) has been shown in meta-analyses to be as effective as longer antibiotic treatment for a range of mild to moderate infections. A landmark trial in critically ill patients with ventilator-associated pneumonia showed that mortality and relapse rates were non-inferior in patients who received 8 vs 15 days of treatment. Similar adequately powered randomized trial evidence is lacking for the treatment of patients with bloodstream infections caused by a wide spectrum of organisms.

Interventions

  • OTHER 7 days of adequate antibiotic treatment
  • OTHER 14 days of adequate antibiotic treatment.

Study Locations (20)

Victoria

  • Ballarat Hospital - Ballarat
  • Bendigo Hospital - Bendigo
  • Casey Hospital - Berwick
  • Monash Medical Centre - Clayton
  • Dandenong Hospital- Monash Health - Dandenong
  • Frankston Hospital - Frankston
  • Peninsula Private Hospital - Langwarrin
  • Cabrini Health - Malvern

New South Wales

  • Bankstown Hospital - Bankstown
  • St Vincent's Hospital - Darlinghurst
  • St. George Hospital - Kogarah
  • John Hunter Hospital - New Lambton Heights
  • Westmead Hospital - Westmead
  • Wollongong Hospital ICU - Wollongong

Western Australia

  • Fiona Stanley Hospital - Murdoch
  • St John of God Hospital - Subiaco

New York

  • NYU School of Medicine - New York

Ohio

  • Cleveland Clinic - Cleveland

Queensland

  • Sunshine Coast University Hospital - Birtinya

Alberta

  • Foothills Hospital - Calgary

Trial Details

FieldValue
Enrollment Target 3,622 participants
Start Date 2017-02-24
Est. Completion 2023-08-03
Phase NA

What the Registry Record Tells You About NCT03005145

The ClinicalTrials.gov registry entry for NCT03005145 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 3,622 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,524-participant average among 90 other Sepsis trials with a reported enrollment target (44% lower). The listed sponsor is Sunnybrook Health Sciences Centre, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Sepsis appearing as the primary indexed condition, and to 2 interventions - of which 7 days of adequate antibiotic treatment is the first listed.

NCT03005145 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Victoria, New South Wales, Western Australia.

Frequently Asked Questions

What is clinical trial NCT03005145 about?

NCT03005145 is a clinical study titled "Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness". The World Health Organization, U.S. Centers for Disease Control and Prevention, Association of Medical Microbiology and Infectious Diseases (AMMI) Canada, and Health Canada have all declared antimicrobial resistance a global threat to health, based on rapidly increasing resistance rates and declinin...

What is the current status of trial NCT03005145?

This trial is currently completed. It is a NA study. The enrollment target is 3,622 participants. The study started on 2017-02-24. Estimated completion is 2023-08-03.

What conditions does trial NCT03005145 study?

This clinical trial studies the following conditions: Sepsis, Bacteremia, Critically Ill, Mortality, Intensive Care.

What interventions are being tested in trial NCT03005145?

The interventions under investigation include: 7 days of adequate antibiotic treatment (OTHER), 14 days of adequate antibiotic treatment. (OTHER).

Who is sponsoring clinical trial NCT03005145?

This trial is sponsored by Sunnybrook Health Sciences Centre, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03005145 being conducted?

This trial has 20 study locations across New York, Ohio, New South Wales, Queensland, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sepsis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.